Organic & Biomolecular Chemistry · 2005 · 100 citations · 26 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryPsychopharmacologyStructure-activity RelationshipsCannabinoid PharmacologyLigand BindingCannabinoid Receptor PharmacologyCannabinoid Structure-activity Relationships
(-)-Cannabidiol (CBD) is a major, non psychotropic constituent of cannabis. It has been shown to cause numerous physiological effects of therapeutic importance. We have reported that CBD derivatives in both enantiomeric series are of pharmaceutical interest. Here we describe the syntheses of the major CBD metabolites, (-)-7-hydroxy-CBD and (-)-CBD-7-oic acid and their dimethylheptyl (DMH) homologs, as well as of the corresponding compounds in the enantiomeric (+)-CBD series. The starting materials were the respective CBD enantiomers and their DMH homologs. The binding of these compounds to the CB(1) and CB(2) cannabinoid receptors are compared. Surprisingly, contrary to the compounds in the (-) series, which do not bind to the receptors, most of the derivatives in the (+) series bind to the CB(1) receptor in the low nanomole range. Some of these compounds also bind weakly to the CB(2) receptor.
26
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
William A. Devane, Aviva Breuer, Roger G. Pertwee et al. · Science · 1992 · 5.6K citations
Molecular characterization of a peripheral receptor for cannabinoids
Sean Munro, Kerrie L. Thomas, Muna Abu-Shaar · Nature · 1993 · 5.1K citations
Tiziana Bisogno, Luciano De Petrocellis, Susanna Tchilibon et al. · British Journal of Pharmacology · 2001 · 1.3K citations · Full text
Anne‐Marie Malfait, Ruth Gallily, Percy F. Sumariwalla et al. · Proceedings of the National Academy of Sciences · 2000 · 663 citations